Munich, Germany – 09 November 2023 – Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the enrolment of their first participant in the United States, an important milestone for the i-GAIN natural history study of people who have been diagnosed with geographic atrophy (GA), secondary to age-related macular degeneration (AMD).
The i-GAIN (investigating Geographic Atrophy Insights) study is a non-interventional study for participants who have a confirmed diagnosis of GA. The study, which has surpassed 100 participants in the UK, will now expand to include 10 centres in the United States. i-GAIN is designed to evaluate the relationship between genetics, blood biomarkers evaluated using the proprietary Complement Precision Medicine (CPM) Platform, and phenotypic changes in the eyes of people with GA. Data from the i-GAIN study will ultimately support the clinical development of CTx001, an innovative gene therapy asset for the treatment of GA, enabling the identification and stratification of patients with complement-driven AMD for future interventional studies.
Dr Parisa Zamiri, Chief Medical Officer at Complement Therapeutics said, “Achieving this milestone is a great step in expanding our study and ensuring we capture meaningful, clinically relevant data to better understand geographic atrophy. We look forward to analysing this extensive database which will provide deeper insights into how the disease progresses.”
“An expanded natural history study will provide an in-depth, data-driven comprehension of a complex and heterogeneous disease that is GA, which will contribute to the clinical development of our innovative complement-targeting gene therapy approach to provide optimised solutions for patients,” said Dr Rafiq Hasan, Chief Executive Officer at Complement Therapeutics.
Company Contact
Dr Rafiq Hasan, CEO
Complement Therapeutics Ltd
Email: info@complementtx.com